{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:46:31Z","timestamp":1793353591840,"version":"4.5.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ygyno.2025.11.014","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T23:33:04Z","timestamp":1764199984000},"page":"109-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Updates to post-treatment surveillance after curative intent treatment for patients with gynecologic cancers: A Society of Gynecologic Oncology clinical practice statement"],"prefix":"10.1016","volume":"204","author":[{"given":"Ritu","family":"Salani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Atallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda N.","family":"Fader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Frimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Obermair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene","family":"Pareja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ygyno.2025.11.014_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.ygyno.2025.11.014_bb0010","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.ygyno.2025.11.014_bb0015","first-page":"409","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"72","author":"Miller","year":"2022","journal-title":"CA Cancer J. Clin."},{"issue":"19","key":"10.1016\/j.ygyno.2025.11.014_bb0020","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1200\/JCO.23.02475","article-title":"Surveillance Imaging after curative-intent treatment for Cancer: benefits, harms, and evidence","volume":"42","author":"Wilson","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2025.11.014_bb0025","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jamaoncol.2022.0009","article-title":"Racial and ethnic differences in hysterectomy-corrected uterine Corpus Cancer mortality by stage and histologic subtype","volume":"8","author":"Clarke","year":"2022","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2025.11.014_bb0030","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.ygyno.2020.12.021","article-title":"Endometrial cancer: a society of gynecologic oncology evidence-based review and recommendations","volume":"160","author":"Hamilton","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.11.014_bb0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2017.03.022","article-title":"An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations","volume":"146","author":"Salani","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2025.11.014_bb0040","doi-asserted-by":"crossref","first-page":"181","DOI":"10.6004\/jnccn.2023.0006","article-title":"Uterine neoplasms, version 1.2023, NCCN clinical practice Guidelines in oncology","volume":"21","author":"Abu-Rustum","year":"2023","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.ygyno.2025.11.014_bb0045","author":"Rimel"},{"issue":"33","key":"10.1016\/j.ygyno.2025.11.014_bb0050","first-page":"3817","article-title":"Effectiveness of intensive versus minimalist follow-up regimen on survival in patients with endometrial Cancer (TOTEM study): a randomized, pragmatic, parallel group","volume":"40","author":"Zola","year":"2022","journal-title":"Multicenter Trial. J. Clin. Oncol."},{"issue":"33","key":"10.1016\/j.ygyno.2025.11.014_bb0055","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1200\/JCO.22.01551","article-title":"Surveillance strategies in endometrial Cancer care: why less represents Progress","volume":"40","author":"Beavis","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.11.014_bb0060","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ygyno.2024.06.020","article-title":"Effect of reduced follow-up care on patient satisfaction with care among patients with endometrial cancer: the ENSURE randomized controlled trial","volume":"188","author":"Ezendam","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2025.11.014_bb0065","doi-asserted-by":"crossref","first-page":"417","DOI":"10.5468\/ogs.19169","article-title":"Fertility-sparing treatment in early endometrial cancer: current state and future strategies","volume":"63","author":"Obermair","year":"2020","journal-title":"Obstet Gynecol Sci."},{"issue":"2","key":"10.1016\/j.ygyno.2025.11.014_bb0070","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/ijgo.15146","article-title":"Conservative re-treatment of women with atypical endometrial hyperplasia and early endometrial carcinoma: we can hope, at least","volume":"165","author":"Raffone","year":"2024","journal-title":"Int. J. Gynaecol. Obstet."},{"issue":"1","key":"10.1016\/j.ygyno.2025.11.014_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11010183","article-title":"Conservative surgery in endometrial Cancer","volume":"11","author":"Gallo","year":"2021","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.ygyno.2025.11.014_bb0080","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ygyno.2020.11.007","article-title":"Continued medical treatment for persistent early endometrial cancer in young women","volume":"160","author":"Cho","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.11.014_bb0085","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ygyno.2021.01.001","article-title":"Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer","volume":"161","author":"Novikova","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.11.014_bb0090","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231157645","article-title":"Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS)","volume":"15","author":"Perez-Fidalgo","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2025.11.014_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/diseases12090200","article-title":"Survival trends for uterine sarcomas from a tertiary center: the Oxford experience","volume":"12","author":"Aggarwal","year":"2024","journal-title":"Diseases"},{"issue":"9","key":"10.1016\/j.ygyno.2025.11.014_bb0100","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa2403394","article-title":"Doxorubicin-Trabectedin with Trabectedin maintenance in Leiomyosarcoma","volume":"391","author":"Pautier","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ygyno.2025.11.014_bb0105","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ygyno.2008.01.030","article-title":"Role of PET or PET\/CT in the post-therapy surveillance of uterine sarcoma","volume":"109","author":"Park","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.11.014_bb0110","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ygyno.2011.10.010","article-title":"Endometrial stromal sarcoma: analysis of recurrence following adjuvant treatment","volume":"125","author":"Beck","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"10125","key":"10.1016\/j.ygyno.2025.11.014_bb0115","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2025.11.014_bb0120","author":"SEER Explorer: An interactive website for SEER cancer statistics SEER website: SEER"},{"issue":"12","key":"10.1016\/j.ygyno.2025.11.014_bb0125","doi-asserted-by":"crossref","first-page":"7193","DOI":"10.7314\/APJCP.2013.14.12.7193","article-title":"Detection of recurrence in a surveillance program for epithelial ovarian cancer","volume":"14","author":"Suprasert","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"3A","key":"10.1016\/j.ygyno.2025.11.014_bb0130","first-page":"1551","article-title":"Evaluation of CA125, physical and radiological findings in follow-up of ovarian cancer patients","volume":"25","author":"Fehm","year":"2005","journal-title":"Anticancer Res."},{"issue":"3","key":"10.1016\/j.ygyno.2025.11.014_bb0135","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/IGC.0b013e3181a1cc02","article-title":"Are surveillance procedures of clinical benefit for patients treated for ovarian cancer?: a retrospective Italian multicentric study","volume":"19","author":"Gadducci","year":"2009","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2025.11.014_bb0140","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/ijgc-2021-002885","article-title":"Ovarian cancer recurrence detection may not require in-person physical examination: an MSK team ovary study","volume":"32","author":"Feinberg","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"7","key":"10.1016\/j.ygyno.2025.11.014_bb0145","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/ijgc-2022-003506","article-title":"The utility of physical examination in ovarian cancer recurrence detection: a retrospective analysis informing virtual surveillance care","volume":"32","author":"Janke","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"9747","key":"10.1016\/j.ygyno.2025.11.014_bb0150","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(10)61268-8","article-title":"Early versus delayed treatment of relapsed ovarian cancer (MRC OV05\/EORTC 55955): a randomised trial","volume":"376","author":"Rustin","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ygyno.2025.11.014_bb0155","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","article-title":"ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease","volume":"35","author":"Ledermann","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2025.11.014_bb0160","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0090-8258(21)00775-7","article-title":"RECIST\/CA-125 progression-free survival and the role of CA-125 surveillance in the phase III PAOLA-1\/ENGOT-ov25 trial evaluating maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian carcinoma","volume":"162","author":"Hietanen","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2025.11.014_bb0165","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.21037\/gs-20-544","article-title":"Role of biomarkers for early detection of ovarian cancer recurrence","volume":"9","author":"Giampaolino","year":"2020","journal-title":"Gland Surg."},{"issue":"21","key":"10.1016\/j.ygyno.2025.11.014_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16213566","article-title":"The role of HE4 in the follow-up of advanced ovarian, fallopian tube, and primary peritoneal Cancer-CEEGOG OX-01 study","volume":"16","author":"Presl","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.ygyno.2025.11.014_bb0175","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ygyno.2010.01.014","article-title":"Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias?","volume":"117","author":"Tanner","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2025.11.014_bb0180","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.23.01182","article-title":"Poor concordance between Cancer Antigen-125 and RECIST assessment for progression in patients with platinum-sensitive relapsed ovarian Cancer on maintenance therapy with a poly(ADP-ribose) polymerase inhibitor","volume":"42","author":"Tjokrowidjaja","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2025.11.014_bb0185","first-page":"207","article-title":"(18)F-FDG PET\/CT in ovarian cancer recurrence: clinical impact, correlation with ceCT and CA-125, and prognostic value","volume":"40","author":"Garcia-Talavera","year":"2021","journal-title":"Rev. Esp. Med. Nucl. Imagen Mol. (Engl. Ed)."},{"issue":"1067","key":"10.1016\/j.ygyno.2025.11.014_bb0190","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20160468","article-title":"Whole-body diffusion-weighted magnetic resonance imaging in the diagnosis of recurrent ovarian cancer: a clinical feasibility study","volume":"89","author":"Michielsen","year":"2016","journal-title":"Br. J. Radiol."},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2025.11.014_bb0195","doi-asserted-by":"crossref","first-page":"i20","DOI":"10.1093\/annonc\/mdw090","article-title":"Management of borderline ovarian tumors","volume":"27","author":"du Bois","year":"2016","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2025.11.014_bb0200","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1111\/jog.16085","article-title":"Oncological outcomes and risk factors for recurrence of mucinous borderline ovarian tumors: a 15-year experience at a tertiary center","volume":"50","author":"Poonyakanok","year":"2024","journal-title":"J. Obstet. Gynaecol. Res."},{"issue":"3","key":"10.1016\/j.ygyno.2025.11.014_bb0205","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ygyno.2021.03.023","article-title":"Fertility-sparing treatment in advanced-stage serous borderline ovarian tumors. An analysis from the MITO14 study database","volume":"161","author":"Falcone","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.11.014_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010073","article-title":"Identifying borderline ovarian tumor recurrence using routine ultrasound follow-up","volume":"15","author":"Lazurko","year":"2022","journal-title":"Cancers (Basel)."},{"issue":"13","key":"10.1016\/j.ygyno.2025.11.014_bb0215","article-title":"Evaluation of borderline ovarian tumor recurrence rate after surgery with or without fertility-sparing approach: results of a retrospective analysis","volume":"11","author":"Pecorino","year":"2023","journal-title":"Healthcare (Basel)"},{"issue":"2","key":"10.1016\/j.ygyno.2025.11.014_bb0220","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ygyno.2020.05.007","article-title":"Contemporary management of ovarian germ cell tumors and remaining controversies","volume":"158","author":"Veneris","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.11.014_bb0225","author":"NCCN Guidelines: Uterine Neoplasms"},{"issue":"9 Suppl 3","key":"10.1016\/j.ygyno.2025.11.014_bb0230","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1097\/IGC.0000000000000249","article-title":"Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumors","volume":"24","author":"Ray-Coquard","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"8","key":"10.1016\/j.ygyno.2025.11.014_bb0235","doi-asserted-by":"crossref","first-page":"512","DOI":"10.6004\/jnccn.2024.0052","article-title":"NCCN Guidelines(R) insights: ovarian Cancer\/fallopian tube Cancer\/primary peritoneal Cancer, version 3.2024","volume":"22","author":"Liu","year":"2024","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.ygyno.2025.11.014_bb0240","author":"Howlader"},{"issue":"12","key":"10.1016\/j.ygyno.2025.11.014_bb0245","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.6004\/jnccn.2023.0062","article-title":"NCCN Guidelines(R) insights: cervical Cancer, version 1.2024","volume":"21","author":"Abu-Rustum","year":"2023","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"8","key":"10.1016\/j.ygyno.2025.11.014_bb0250","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1034\/j.1600-0412.2001.800721-2.x","article-title":"Recurrent cervical cancer: detection and prognosis","volume":"81","author":"Duyn","year":"2002","journal-title":"Acta Obstet. Gynecol. Scand."},{"issue":"3","key":"10.1016\/j.ygyno.2025.11.014_bb0255","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jasc.2021.12.004","article-title":"Utility of routine cytology in detecting asymptomatic cervical cancer recurrence","volume":"11","author":"McDowell","year":"2022","journal-title":"J. Am. Soc. Cytopathol."},{"issue":"7","key":"10.1016\/j.ygyno.2025.11.014_bb0260","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/ijgc-2021-003302","article-title":"Vaginal vault smear cytology in detection of recurrence after hysterectomy for early cervical cancer","volume":"32","author":"Grace","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2025.11.014_bb0265","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ygyno.2015.02.021","article-title":"Improving quality and decreasing cost in gynecologic oncology care. Society of gynecologic oncology recommendations for clinical practice","volume":"137","author":"Rimel","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2025.11.014_bb0270","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ygyno.2021.11.014","article-title":"The role of high-risk HPV testing in cervical cancer surveillance","volume":"164","author":"Aryasomayajula","year":"2022","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2025.11.014_bb0275","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2020.31.e20","article-title":"Human papillomavirus (HPV) DNA detection in uterine cervix cancer after radiation indicating recurrence: a systematic review and meta-analysis","volume":"31","author":"Sabeena","year":"2020","journal-title":"J. Gynecol. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2025.11.014_bb0280","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S1470-2045(23)00467-9","article-title":"Optimising follow-up strategy based on cytology and human papillomavirus after fertility-sparing surgery for early stage cervical cancer: a nationwide, population-based, retrospective cohort study","volume":"24","author":"Schuurman","year":"2023","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2025.11.014_bb0285","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ygyno.2016.05.030","article-title":"Role of cervical cytology in surveillance after radical trachelectomy for cervical cancer","volume":"142","author":"Brown","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2025.11.014_bb0290","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/1471-0528.12460","article-title":"Evaluating PET-CT in routine surveillance and follow-up after treatment for cervical cancer: a cost-effectiveness analysis","volume":"121","author":"Auguste","year":"2014","journal-title":"BJOG"},{"issue":"11","key":"10.1016\/j.ygyno.2025.11.014_bb0295","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1136\/ijgc-2023-004703","article-title":"Prognostic significance of delayed complete metabolic response on PET\/CT after primary chemoradiation treatment of cervical cancer","volume":"33","author":"Michaan","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2025.11.014_bb0300","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1097\/IGC.0000000000000705","article-title":"Does routine posttreatment PET\/CT add value to the Care of Women with Locally Advanced Cervical Cancer?","volume":"26","author":"Phippen","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"11","key":"10.1016\/j.ygyno.2025.11.014_bb0305","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1002\/ijc.30900","article-title":"Vulvar cancer in high-income countries: increasing burden of disease","volume":"141","author":"Kang","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2025.11.014_bb0310","series-title":"Berek & Hacker\u2019s Gynecologic Oncology","author":"Berek","year":"2021"},{"issue":"2","key":"10.1016\/j.ygyno.2025.11.014_bb0315","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ygyno.2013.07.082","article-title":"A review of complications associated with the surgical treatment of vulvar cancer","volume":"131","author":"Wills","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"149","key":"10.1016\/j.ygyno.2025.11.014_bb0320","first-page":"22394","article-title":"Morbidity related to the groin lymph node dissection for vulvar cancer","volume":"6","author":"Barlow","year":"2019","journal-title":"Int. J. Gynecol. Clin. Pract."},{"issue":"2","key":"10.1016\/j.ygyno.2025.11.014_bb0325","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17020186","article-title":"Management of Patients with vulvar cancers: a systematic comparison of international Guidelines (NCCN-ASCO-ESGO-BGCS-IGCS-FIGO-French Guidelines-RCOG)","volume":"17","author":"Restaino","year":"2025","journal-title":"Cancers (Basel)."},{"issue":"3","key":"10.1016\/j.ygyno.2025.11.014_bb0330","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030831","article-title":"Groin surveillance by serial ultrasonography rather than sentinel node biopsy or Inguinofemoral lymphadenectomy for patients with vulvar Cancer: a pilot study","volume":"15","author":"Hacker","year":"2023","journal-title":"Cancers (Basel)."},{"issue":"11","key":"10.1016\/j.ygyno.2025.11.014_bb0335","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1111\/1471-0528.15341","article-title":"The efficacy of ultrasound in the follow up after a negative sentinel lymph node in women with vulvar cancer: a prospective single-Centre study","volume":"125","author":"Pouwer","year":"2018","journal-title":"BJOG"},{"issue":"9","key":"10.1016\/j.ygyno.2025.11.014_bb0340","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1136\/ijgc-2022-003616","article-title":"HPV-independent and HPV-associated vulvar squamous cell carcinoma: two different cancers","volume":"32","author":"Eva","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"11S","key":"10.1016\/j.ygyno.2025.11.014_bb0345","first-page":"S442","article-title":"ACR appropriateness criteria(R) staging and follow-up of primary vaginal Cancer","volume":"18","author":"Expert Panel on GYN","year":"2021","journal-title":"J. Am. Coll. Radiol."},{"issue":"2","key":"10.1016\/j.ygyno.2025.11.014_bb0350","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ygyno.2020.08.036","article-title":"Management and outcomes of primary vaginal Cancer","volume":"159","author":"Yang","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2025.11.014_bb0355","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.annonc.2025.05.533","article-title":"Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses","volume":"36","author":"Mayadev","year":"2025","journal-title":"Ann. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.ygyno.2025.11.014_bb0360","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1200\/JCO.2025.43.16_suppl.5512","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for endometrial cancer: longitudinal changes in circulating tumor DNA","volume":"43","author":"Westin","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2025.11.014_bb0365","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1158\/1078-0432.CCR-22-1134","article-title":"High-sensitivity mutation analysis of cell-free DNA for disease monitoring in endometrial Cancer","volume":"29","author":"Ashley","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ygyno.2025.11.014_bb0370","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ygyno.2022.09.004","article-title":"Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer","volume":"167","author":"Hou","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.11.014_bb0375","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ygyno.2024.11.002","article-title":"The prognostic value of tumor-informed minimal residual disease detection using circulating tumor DNA in first-line treatment of ovarian cancer","volume":"192","author":"Shu","year":"2025","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825010984?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825010984?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T06:38:07Z","timestamp":1764225487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825825010984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":75,"alternative-id":["S0090825825010984"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.11.014","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates to post-treatment surveillance after curative intent treatment for patients with gynecologic cancers: A Society of Gynecologic Oncology clinical practice statement","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}